Connected With Latham

California-based venture capital and growth firm with more than US$3 billion under management, NewView Capital invests in high-potential technology companies on a primary, secondary, or hybrid basis. Founded in 2018, NewView has emerged as an early leader in the secondary market, taking a boutique, high-conviction approach to backing category-defining companies. Latham has advised NewView on a ran...

Residential real estate platform Opendoor puts homeowners in control by replacing the traditional, passive home-selling process with a streamlined e-commerce system. Founded in 2014, Opendoor has since expanded its reach across the lower 48 states, building out a partner network and tackling the complex ecosystem of utilities, title, escrow, and mortgage that surrounds every home sale. In this epi...

The corporate venture capital arm of Rakuten Group, Rakuten Capital invests in innovative startups across fintech, AI, and other high-growth sectors. Since its founding in 2014, Rakuten Capital has invested in companies like Lyft, Pinterest, Careem, and Upstart, establishing itself as a distinctive force in corporate venture investing. In this episode of  Connected With Latham , Haim Zaltzman , Gl...

Founded in 2020, Axiado deploys hardware-anchored, AI-driven platform security by embedding silicon directly on the rack, protecting AI and cloud infrastructure against cyberattacks in real time. Latham represented Axiado in its oversubscribed US$100+ million Series C+ funding round. In this episode of  Connected With Latham , Haim Zaltzman , Global Vice Chair of Latham's Emerging Companies & Grow...

Celera Semiconductor aims to radically accelerate the development of analog semiconductor chips using AI. Founded in 2018, Celera has raised US$34 million in funding, including a recent Series A led by Maverick Silicon that Latham advised on. The company partners with the world's largest independent analog fab to engage customers in high-growth industries like data centers, consumer electronics, a...

The Trump administration has advanced many policy initiatives in the drug pricing and market access area, and CMS —the Centers for Medicare & Medicaid Services — is the agency at the heart of many of these efforts. Rujul Desai, Senior Counselor to CMS and former Deputy General Counsel at the Department of Health & Human Services, joins Washington, D.C. partner  Chris Schott and associate Danny Mac...

Washington, D.C. partner Chris Schott , and associates Danny Machado and Evan Rothkoff , share observations and insights from the recent Centers for Medicare & Medicaid Services (CMS) Quality Conference and the American Health Law Association's Institute on Medicare and Medicaid Payment Issues conference. They also discuss updates that government speakers shared at these events.   Also check out o...

A-Frame Brands identifies emerging signals in culture, consumer behavior, and category white space — then moves fast to bring the right products to shelf. They work two ways: co-creating private-label and exclusive product lines with the world's leading retailers, building a portfolio of standalone brands with world-class talent partners across beauty, personal care, fragrance, home care, and pet...

Over two decades, more than 350 Latham lawyers have taken on Holocaust reparations matters, helping Holocaust survivors apply for pensions for work performed in Nazi-controlled ghettos during World War II. In this episode of Connected With Latham , Laura Atkinson-Hope , Public Service Counsel and Director of Global Pro Bono at Latham, sits down with Anna Bravo, Attorney Support Manager and longtim...

ParaFi Capital is an alternative asset management and technology firm focused on blockchain and digital assets. Founded in 2018, the firm was among the earliest institutional investors in the blockchain industry and has evolved into a trusted partner to leading institutions around the world. Latham has advised ParaFi on a range of strategic investments across the digital asset ecosystem, including...

Founded in 2013, Fetch is a daily rewards destination for consumers and brands, turning everyday actions like shopping, dining out, and playing games into tangible value for consumers while delivering measurable advertising for consumer, retail, and restaurant brands. Latham represented Fetch on a series of strategic growth financing transactions in 2025. In this episode of Connected With Latham ,...

States continue to expand their review of healthcare transactions involving private equity, real estate investment trusts, management services organizations, and other investors. Join Washington, D.C. counsel Nicole Liffrig Molife , Los Angeles counsel Yanyan Zhou , and Washington, D.C. associate Margaret Rote as they discuss how the increased level of state regulatory oversight affect health serv...

The drug pricing and market access policy space saw a lot of change in 2025, and the pace is not slowing down. In this episode of Connected With Latham, pharmaceutical industry veteran Sabrina Aery , founder of Aery Policy and Access Partners, joins Washington, D.C. partner Chris Schott and associate Danny Machado for a wide-ranging discussion of key 2025 takeaways and what to expect in 2026.   Al...

In this episode of Connected with Latham, complementing Latham's " 10 Key Focus Areas for UK-Regulated Financial Services Firms in 2026" report, London partners Rob Moulton and Nicola Higgs and counsel Becky Critchley discuss the key trends for financial services firms in 2026. Amongst other topics, they discuss the Leeds Reforms, the ESG landscape, and enforcement trends.   This podcast is provid...

The pharmaceutical industry has seen major legal and policy changes in recent years, from the Inflation Reduction Act to the Trump administration's aggressive pricing policies. In this episode of Connected With Latham, Mike Domanico, a pharmaceutical industry veteran with experience in Big 4, brand drugs, biosimilars, and generics, and most recently Vice President of Revenue Finance, joins Washing...

Recent FDA actions are reshaping key aspects of drug and biologic development, including the Commissioner's National Priority Voucher program, the "plausible mechanism" pathway for personalized therapies, and new draft guidance aimed at streamlining biosimilars and interchangeables. Join Washington, D.C. partner Nathan Beaton and counsel Monica Groat and Chad Jennings as they discuss how these mov...

Government pricing assessments are an important tool to help pharmaceutical manufacturers review their government price reporting function. They can also help uncovering strategic benefits and opportunities. In this episode of Connected With Latham, Eliza Biedziak , Managing Director at Ernst & Young LLP, joins Washington, D.C.  partner Chris Schott and associate Danny Machado to explore how these...

The new FDA Commissioner's National Priority Voucher (CNPV) pilot program promises to reduce recipients' application review times from 10-12 months to just 1-2 months. As part of the Trump administration's push for most favored nation (MFN) pricing, drug affordability is one criterion for vouchers, marking FDA's entry into the drug pricing fray. In this episode of Connected With Latham, Washington...

Stakeholders from across the healthcare industry — from manufacturers and consultants to outside counsel and government officials — recently convened in Chicago for the Medicaid Drug Rebate Program Summit 2025. In this episode of Connected With Latham, Washington, D.C. partner Chris Schott , counsel Nicole Liffrig Molife , and associate Danny Machado share impressions and key takeaways from the co...

In this episode of Connected With Latham , London partner Fiona Maclean , Paris partner Jean-Luc Juhan , and London counsel Alain Traill discuss significant new switching requirements due to take effect for data processing services under the EU Data Act.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship betwee...

In this episode of Connected With Latham , London partner Gail Crawford and Frankfurt partner Tim Wybitul discuss the EU Data Act, and what this means for data privacy and cybersecurity practices.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send co...

In this episode of Connected with Latham , London partners Rob Moulton and Nicola Higgs discuss the UK government's plans for the financial services sector, and key takeaways for financial services firms.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not...

Current developments, such as most favored nation (MFN) pricing, grabbed much of the spotlight when key industry stakeholders met in Philadelphia for the Pricing and Contracting USA Conference. In this episode of Connected With Latham , Allan Thoen, Director & Associate General Counsel with Sandoz, joins Washington, D.C. partner Chris Schott and associate Danny Machado to discuss impressions and t...

Stakeholders from across the healthcare industry, including members of Congress, the US Food and Drug Administration, and the Center for Medicare and Medicaid Services, recently convened in Washington D.C. for the Medical Device Manufacturers Association (MDMA) Annual Meeting. In this episode of Connected With Latham, Washington, D.C. partners Chris Schott , Nate Beaton , and Bill McConagha , and...

The "Lowering Drug Prices by Once Again Putting Americans First" Executive Order addresses various FDA matters, such as importation from Canada and accelerated approval of generics and biosimilars. In this episode of Connected With Latham , Washington, D.C. partners Chris Schott , Ben Haas , and Bill McConagha analyze these FDA implications, and explore how the EO overlaps with  five drug pricing...